Choose your next compounds with more of the picture.

Screen absorption, distribution, metabolism and safety in one ADMET workflow. Compare liabilities before committing your next assay budget.

From a compound list to a clearer shortlist

Find liabilities earlier

Review permeability, binding, metabolism and safety signals before advancing a candidate.

Compare endpoints together

See where a compound performs well and where the next experiment should focus.

Fit your R&D workflow

Use interactive predictions or connect the ADMET workflow to your existing screening tools.

Strong measured performance

0.989

DILI AUROC

96 public test compounds · identity, fingerprint and scaffold references excluded.
0.952 with identity/fingerprint exclusions only; same 96 cases.

0.281

Caco-2 MAE, log Papp

Current alternative mode on the 182-case known development panel. Profile mode: 0.914 under its separate reference exclusions.

0.839

CYP3A4 inhibition AUROC

CYP3A4 · 2,467 reference-excluded test cases; AUPRC 0.814.
CYP2C9 AUROC 0.835; CYP2D6 0.821. Full endpoint results in the benchmark.

Eight ADMET endpoint families

Absorption and distribution

Caco-2 permeability, blood-brain barrier classification, aqueous solubility and plasma protein binding.

Metabolism

Intrinsic-clearance and metabolic-stability estimates, plus per-isoform CYP inhibition predictions.

Safety

hERG inhibition estimates and DILI risk, with mechanism and exposure context.

Each endpoint retains its own input and measured scope. Explore the complete performance tables.

Put ADMET screening to work on your library

Tell us which compounds, endpoints and decisions matter. Build a focused pilot around your workflow, with agreed outputs and success criteria.